Medical and Diagnostic Imaging Technology Alert. Imaging Solution for Early Phase Trials; Vendor Neutral Breast Density Analytic Tool; Nanoparticles f

USD 1,500

* Required Fields

USD 1,500

PAY BY INVOICE

Be the first to review this product

This issue profiles an imaging solution for early phase trials, a vendor neutral breast density analytic tool, and nanoparticles for multimodality use.

Table of Contents

Medical and Diagnostic Imaging Technology Alert. Imaging Solution for Early Phase Trials; Vendor Neutral Breast Density Analytic Tool; Nanoparticles for Multimodality UseIn This Issue1. IMAGING SOLUTION FOR EARLY PHASE TRIALS2. VENDOR NEUTRAL BREAST DENSITY ANALYTIC TOOL3. NANOPARTICLES FOR MULTIMODALITY USE4. INNOVATIVE USG PLATFORM FOR FASTER IMAGE ACQUISITION5. MOBILE 3D C-ARMS6. HYBRID IR SYSTEM7. INNOVATIVE STENT PLATFORM TO PREVENT STENT FAILURE8. CARDIOVASCULAR MANAGEMENT SOLUTION FOR BETTER HEALTHCARE MANAGEMENT




Keyword1

Keyword2

Keyword3

Related Research

Release Date : 08-Dec-17

Region : Global

Release Date : 08-Dec-17

Region : Global

Release Date : 01-Dec-17

Region : Global

Release Date : 29-Nov-17

Region : Global

Related Subscription

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.